IntraBio Inc. today announced positive topline results from its pivotal Phase III IB1001-303 clinical trial, "Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Randomized, ...

Topline results show eDSP failed to significantly improve RmICARS scores in ataxia-telangiectasia patients compared with placebo in the NEAT trial.

Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.

Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.

If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Hereditary hemorrhagic telangiectasia (HHT) is characterized by extensive telangiectasias and arteriovenous malformations. The primary clinical manifestation is epistaxis that results in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Encelto is the first FDA-approved treatment for macular ...

Please provide your email address to receive an email when new articles are posted on . Patients with smaller baseline ellipsoid zone area loss and patients with diabetes had better response. Earlier ...

Phase III trial successfully achieved its primary endpoint and key secondary endpoints with high statistical significance Levacetylleucine demonstrated clinically meaningful improvements in ...